Research Monitoring
What changed
in the evidence.
Evidence is not static, and neither are our grades. This is the public log of what moved — new trials, regulatory actions, and every time we changed a compound's grade, with the source that prompted it.
July 2026
Editorial
Synptide launches the compound directory and evidence-grading system
We published canonical, outcome-graded profiles for the first 25 compounds, plus a public A–U evidence framework and this change log.
Evidence-grade change
Semaglutide graded A for cardiovascular risk reduction on SELECT evidence
We set semaglutide's cardiovascular-outcome grade to A after the SELECT trial's 20% reduction in major cardiovascular events in people with obesity but without diabetes.